TUESDAY  MAY 13, 1997

08:15-09:00  Registration and Continental Breakfast

WELCOMING STATEMENTS

09:00-09:10  Dr P. Chahinian (New York, NY)
09:10-09:20  Dr J. Glick (Philadelphia, PA)

Symposium I: BIOLOGY/CARCINOGENESIS

Chair: Dr. M.-C. Jaurand (Créteil, France), Dr. Brenda Gerwin (Bethesda, USA)

09:20-09:35  Dr J. Bignon (Paris, FRANCE)  Historical Overview

09:35-09:55  Dr A. Buard (Créteil, France) "Activation of the JAK/STAT signalling pathway in IFN-treated human mesothelioma cell lines"  B1

09:55-10:15  Dr S. Faux (Burlington, VT) "Involvement of Ca^{2+} in c-fos transcription factor induction by crocidolite asbestos in rat pleural mesothelial (RPM) cells"  B2

10:15-10:35  Dr P. Ferriola (Research Triangle Park, NC) "Alterations in expression of Bcl2 family genes by fibrous particulates in pleural mesothelial cells"  B3

10:35-10:50  Coffee Break

10:50-11:10  Dr K. Dobra (Huddinge, Sweden) "Proteoglycan synthesis by epithelial and fibrous mesothelioma cells"  B4

11:10-11:30  Dr F. Hervé (Créteil, France) "Study of the microheterogeneity of 1-acid glycoprotein and its genetic variants in malignant mesothelioma"  B5

11:30-11:45  General Discussion

11:45-14:00  LUNCH and POSTER VIEWING

14:00-14:20  Dr S. Mutsaers (London, UK) "Malignant mesothelioma cells produce higher levels of procollagen than normal mesothelial cells in vitro, and are further stimulated by TGF-β1"  B6

14:20-14:40  Dr R. Warn (Norwich, UK) "Effects of hepatocyte growth factor/scatter factor and ECM constituents on the spread and motility of mesothelioma cells in culture."  B7

14:40-15:00  Dr S Mutsaers (London, UK) "Hepatocyte growth factor/scatter factor stimulates mesothelial cell migration and proliferation by an autocrine mechanism."  B8

15:00-15:20  Dr P. Harvey (Norwich, UK) "Hepatocyte growth factor/scatter factor and its receptor, MET, in human malignant mesotheliomas. Possible roles in pathogenesis."  B9
15:20-15:40 COFFEE BREAK

15:40-16:00 Dr J.-B. Prins (Rotterdam, THE NETHERLANDS) “Binding of nuclear factors to the platelet-derived growth factor B chain gene promoter in malignant mesothelioma.” B10

16:00-17:00 GENERAL DISCUSSION and POSTER REVIEW

Posters:

Dr K. Takabe (Kanagawa, JAPAN) “Mineral fiber content in pleural plaques of patients with malignant mesothelioma” BP1

Dr A. Sahu (Lucknow, INDIA) “Responses of the pleura induced by amosite asbestos and preventive strategy” BP2

Dr L.N. Pylev (Moscow, RUSSIA) “Changes of rat mesothelial cell properties in processes of spontaneous and asbestos-induced transformation in culture” BP3

Dr L.N. Pylev (Moscow, RUSSIA) “Pathogenesis of experimental pleural mesothelioma” BP4

Dr S. Kumar-Singh (Antwerp, BELGIUM) “Malignant mesothelioma cell lines over express vascular endothelial growth factor and basic endothelial growth factor.” BP5

Dr S. Kumar-Singh (Antwerp, BELGIUM) “BFGF has a prognostic value in malignant mesothelioma.” BP6

17:00-18:00 Cocktail Reception
WEDNESDAY MAY 14, 1997

08:00-08:30  Registration and Continental Breakfast

08:30-10:15  Symposium: IMMUNOLOGY

  Chair: Dr B. Robinson (Perth, Australia)

  08:30-08:45  Dr L. Caminschi (Perth, Australia) "Systemic, intratumoral and paracrine delivery of IL-12 prevents or delays the onset of murine malignant mesothelioma" 11

  08:45-08:55  Dr E. Kang (Philadelphia, USA) "Lack of correlation between stage of mesothelioma and ability to mount an immune response" 13

  08:55-09:05  Dr A. Marzo (Perth, Australia) "Blockade of tumor-derived TGF-β in vivo using antisense oligonucleotides" 14

  09:05-09:20  Dr L. Mutti (Veruno, Italy) "Mesothelioma cells can present recall antigens in vitro to autologous blood CD4+ lymphocytes" 15

  09:20-09:35  Dr C. Porta (Veruno, Italy) "IL2 can affect directly the growth of mesothelioma cells" 16

  09:35-10:00  Discussion

  10:00-10:15  Coffee Break

10:15-12:30  Symposium: GENETICS/SV40

  Chair: Dr M. Carbone (Chicago, USA), Dr J. Testa (Philadelphia, USA)

  10:15-10:30  Dr A. Kane (Providence, USA) "Increased sensitivity of p53-deficient mice to induction of mesothelioma by crocidolite asbestos fibers" G1

  10:30-10:45  Dr J. Cheng (Philadelphia, USA) "Frequent alterations of NF2 and deletion of chromosome 22q12 in malignant mesothelioma. Evidence for a two-hit mechanism of NF2 inactivation" G2

  10:45-11:00  Dr A. Boylan (Charleston, USA) "Differential expression of three novel genes in mesothelioma cells" G3

  11:00-11:15  Dr D. Bell (Philadelphia, USA) "Multiple regions of allelic loss from chromosome arm 6q in malignant mesothelioma" G4

11:15-11:25  Discussion
11:25-11:40  Dr P. Rizzo (Chicago, USA)  "Simian virus 40-like (SV40) sequences in human malignant mesothelioma"  S1

11:40-11:55  Dr A. Giordano (Philadelphia, USA)  "The retinoblastoma family and simian virus-40 large T antigen interact in human mesotheliomas"  S2

11:55-12:10  Dr K. Linnainmaa (Helsinki, Finland)  "SV40 virus DNA sequences are not present in the tumor tissue of Finnish mesothelioma patients"  S3

12:10-12:30  Discussion

12:30-13:30  LUNCH AND POSTER VIEWING

13:30-15:00  Symposium: PATHOLOGY

Chair: Dr J. Bignon (Creteil, France), Dr A. Hjerpe (Huddinge, Sweden)

13:30-13:40  Dr A. Hjerpe (Huddinge, Sweden)  "Optimisation of a battery of 9 antibodies for the differentiation between epithelial mesothelioma and adenocarcinoma"  P1

13:40-13:50  Dr M. Fleming (Baltimore, USA)  "Desmoplastic mesothelioma (DM) is distinguishable from chronic fibrosing pleuritis (CFP) by specific cytologic, histologic, and immunohistochemical (IHC) criteria"  P2

13:50-14:00  Dr A. Peralta Soler (Wynnewood, USA)  "Differential expression of N-cadherin in pleural mesotheliomas and E-cadherin in lung adenocarcinomas in formalin-fixed, paraffin-embedded tissues"  P3

14:00-14:10  Dr M. Kitagawa (Toyama, Japan)  "Mesotheliomas in Japan. Pathology panels reports"  P4

14:10-14:20  Dr A. Donna (Alessandria, Italy)  "AMAD-2 and calretinin. Evaluation of their immunoreactivity with malignant mesothelioma and mesothelial hyperplasia"  P5

14:20-14:30  Dr P. Heldin (Uppsala, Sweden)  "Hyaluronan. Studies on the mechanism of biosynthesis and of interactions with hyaladherins on human mesothelial and malignant mesothelioma cells"  P6

14:30-14:40  Dr J. Roboz (New York, USA).  "Protein-bound serum hyaluronic acid (HA) in mesothelioma and models to study its formation and stepwise decomposition"  P7

14:40-15:00  General Discussion and Poster Review - Coffee break

Posters:

Dr N. Togawa (Hyogo, Japan)  "Clinical evaluation of soluble CD44 levels in patients with malignant mesothelioma"  IP1

Dr M. Shinjo (Hyogo, Japan)  "TPA and CYFRA21-1 in patients with malignant mesothelioma"  IP2
15:00-17:00 Symposium: EPIDEMIOLOGY

Chair: Dr. William Musk (Perth, Australia)

Speakers:

15:00-15:20 Dr W. Musk (Perth, Australia) "The incidence of malignant mesothelioma after occupational and environmental exposure to Western Australian crocidolite." E1

15:20-15:40 Dr A. Karjalainen (Helsinki, Finland) "Mesothelioma in Finland in 1960-95" E2

15:40-16:05 Dr E. Ilgren (Bryn Mawr, USA) "'Best evidence' analysis of the mesothelioma and lung cancer cases in the Libby vermiculite miners and millers." E3

"Preliminary analysis of the Coalinga chrysotile miners and millers and summary of final data from long term inhalational bioassays of rodents exposed to Coalinga chrysotile." E4

16:05-16:20 Dr M. Camus (Westmount, Canada) "Risk assessment for women living in chrysotile mining towns. 1: Environmental exposure assessment." E5

16:20-16:40 Dr B. Case (Westmount, Canada) "(Westmount, Canada) "Risk assessment for women living in chrysotile mining towns. 2: Mesothelioma: observed vs. predicted." E6

General Discussion and Poster Review
THURSDAY MAY 15, 1997

08:30-09:00   Registration and Continental Breakfast

Plenary Session

09:00-15:00   **Symposium: CLINICAL STUDIES**

Chair: Dr C. Boutin (Marseille, France), Dr P. Chahinian (New York, USA), Dr Harvey Pass (Detroit, USA)

Speakers:

09:00-09:30   Dr A. Knuutila (Helsinki, Finland) "Radiological evaluation criteria for malignant pleural mesothelioma. Comparison of CT and MRI" C1

09:30-10:00   Dr L. Tammilehto (Helsinki, Finland) "Factors affecting surgical strategies in patients with malignant pleural mesothelioma" C2

10:00-10:20   Dr P. Baas (Amsterdam, The Netherlands) "Photodynamic therapy with m-THPC as adjuvant treatment for resected malignant mesothelioma." C3

10:20-10:30   Coffee break

10:30-10:45   Dr L. Robinson (Tampa, USA) "Induction chemotherapy in pleural mesothelioma precludes the technical performance of an extrapleural pneumonectomy" C4

10:45-11:00   Dr C. Boutin (Marseille, France) "Malignant pleural mesothelioma. Results of a Phase II trial of combined chemotherapy" C5

11:00-11:15   Dr P. Ruffié (Villejuif, France) "Phase II study of paclitaxel (Taxol) and cisplatin (CDDP) in advanced pleural malignant mesothelioma (MM)" C6

11:15-11:30   Dr T. Nakano (Hyogo, Japan) "A pilot Phase II study of irinotecan (CPT-11) in combination with cisplatin administered intravenously to patients with malignant mesothelioma" C7

11:30-11:45   Dr B. Castagneto (Torino, Italy) "Intracavitary and systemic rIL-2 in the treatment of malignant pleural mesothelioma" C8

11:45-12:00   Discussion

12:00-13:30   LUNCH AND POSTER VIEWING

13:30-14:00   Poster Review and General Discussion
14:00-17:00  Symposium: GENE THERAPY

Chairs: Dr S. Albeida (Philadelphia, USA), Dr L. Kaiser (Philadelphia, USA)

Speakers:

14:00-14:15  Dr S. Albeida "General Approaches to Cancer Gene Therapy"

14:15-14:30  Dr. Bruce Robinson (Perth, Australia) "Immunologic approaches to Gene Therapy"

14:30-14:50  Dr D. Sterman (Philadelphia, USA) "Adenoviral mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy for malignant pleural mesothelioma. Results of a Phase I clinical trial" GT1

14:50-15:10  Dr B. Robinson (Perth, Australia) "Intralesional vaccinia virus-interleukin 2 (VV-IL2) gene therapy in malignant mesothelioma (MM)" GT2

15:10-15:30  Dr K. Molnar-Kimber (Philadelphia, USA) "Adenoviral-based gene therapy for patients with localized mesothelioma. Induced cellular and humoral immune response" GT3

15:30-15:50  Coffee Break

15:50-16:05  Dr K. Gelfand (Philadelphia, USA) "Mesothelioma patients administered recombinant adenoviral-based gene therapy intrapleurally exhibit TH1 cellular immune response" GT4

16:05-16:20  Dr N. Rizk (Philadelphia, USA) "Evaluation of the bystander effect in adenovirus mediated p53 gene therapy" GT6

16:20-16:40: Dr. Larry R. Kaiser  (Philadelphia, USA) "Gene Therapy- New Directions"

16:40-17:00  General Discussion

THURSDAY MAY 15, 1997  Poster Sessions

CLINICAL STUDIES - GENE THERAPY
09:00-17:00

Dr A. Zaccaria (Trieste, Italy): "Malignant pleural mesothelioma. Prognostic factors" CP1

Dr A. Tonomura (Hyogo, Japan): "Immunotherapy using streptococcal preparation OK-432 for the treatment of malignant mesothelioma. A preliminary study" CP2

Dr S. Mikulski (Bloomfield, USA): "The use of Onconase (ONC) for patients (PTS) with advanced malignant mesothelioma (MM)" CP3

Dr M. Lopez (Paris, France): "Local adoptive immunotherapy using IFNγ-activated autologous macrophages in malignant pleural mesothelioma. A phase I/II study." CP4

Dr K. Linnainmaa (Helsinki, Finland): "Individual variation in response to cytostatic chemotherapy in the treatment of mesothelioma. In vitro studies in human cell lines." CP5

Dr L. Coonrod (Philadelphia, USA): "Retinoids augment the bystander effect in HSVtk/GCV mediated gene therapy by enhanced gap junctional intercellular communication." CP6